A generic version of the HIV prevention pill Truvada will be available in the United States by September 2020, a year earlier than expected, according to Gilead Sciences.
When taken daily, Truvada prevents HIV transmission. This approach is called HIV pre-exposure prophylaxis (PrEP).
“Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required,” Douglas Brooks, Gilead’s executive director for community engagement, wrote in an email shared with NBC News by the advocacy group PrEP4All.
A month’s supply of generic Truvada is available in countries around the world for as little as $70, but the drug costs $1,600 to $2,000 in the United States.
Activists launched a campaign to convince Gilead to make the generic drug more widely available to combat the global HIV epidemic.
Subscribe to our YouTube channel:
TICTOC ON SOCIAL:
Follow TicToc on Twitter:
Like TicToc on Facebook:
Follow TicToc on Instagram:
Watch all of TicToc’s videos:
Listen to TicToc’s podcast:
Subscribe to our newsletter:
TicToc by Bloomberg is global news for the life you lead. We are a 24/7 news network that covers breaking news, politics, technology, business and entertainment stories from around the globe, supported by a network of Bloomberg’s 2,700 journalists across 120 countries.